Transcarotid TAVR with the Evolut TAV is an effective, safe approach for patients with unfavorable iliofemoral anatomy and heart teams should become facile with this technique to provide optimal care across the anatomy spectrum.
Abstract
Background
Transcarotid access for transcatheter aortic valve replacement (TAVR) is the most commonly used alternate access in the United States. Real-world evidence on transcarotid access using the Evolut self-expanding valve based on larger numbers of patients may help inform treatment optimization towards better outcomes.
Methods
The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry™ was queried for patients undergoing native TAVR using transcarotid access with an Evolut (January 2015-December 2024). In-hospital, 30-day, and 1-year outcomes are reported.
Results
We identified 2,105 patients (mean age 78.3±7.9 years) with mean Society of Thoracic Surgeons predicted risk of mortality 6.4±5.3. Most were high/extreme surgical risk (60.0%) with New York Heart Association class III/IV heart failure symptoms (66.8%) and mean baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) Score 45.3±25.4. Implant success was 99.6% primarily using general anesthesia (95.8%) with median procedure time of 88.0 (Q1=68.0, Q3=115.0) minutes. Median length of stay was 2.0 (Q1=1.0, Q3=3.0) days; 89.0% were discharged to home. In-hospital, 30-day and 1-year all-cause mortality was 2.1%, 3.8% and 16.5%; stroke occurred in 3.1%, 3.8% and 5.1% of patients, respectively. At 30 days, major vascular complications (1.9%), valve related (0.4%) and non-valve related (10.9%) readmissions were low. The mean change in KCCQ score from baseline to 1-year was +30.5±27.1 points.
Conclusions
Transcarotid TAVR with the Evolut TAV is an effective, safe approach for patients with unfavorable iliofemoral anatomy. Heart teams should become facile with this technique to provide optimal care across the anatomy spectrum.
OBJECTIVES
In high-risk patients, transcatheter mitral valve replacement (TMVR) is an alternative to surgery and transcatheter edge-to-edge repair (TEER). This study aims to evaluate the mid-term results of TMVR with the Tendyne System in a real-world population at a single center.
METHODS
Between November 2018 and D...
L. Besola, Cristina Di Franco, Federico Giorgi et al.· Interdisciplinary cardiovasc...· 0 citations
Background The transaxillary (TxA) approach for minimally invasive aortic valve replacement (MICS-AVR) is a sternum-sparing technique that combines surgical valve replacement with virtually no visible scarring. We report institutional outcomes of the first 1,848 consecutive TxA MICS-AVR procedures. Methods This retrosp...
S. Arzt, K. Alexiou, Ali Taghizadeh-Waghefi et al.· Annals of Cardiothoracic Sur...· 0 citations
BACKGROUND
The JenaValve Trilogy Transcatheter Heart Valve System (Trilogy) is a CE-marked transcatheter aortic valve replacement device designed for the treatment of symptomatic aortic regurgitation. Despite its unique indication, data from large cohorts remain limited. This study aimed to evaluate procedural characte...
H. Wienemann, Sara Yousefzada, M. Rogmann et al.· Circulation. Cardiovascular...· 0 citations
BACKGROUND
Data on early outcomes of the novel balloon-expandable (BE) Octapro transcatheter heart valve (THV) in real-world practice are limited. We sought to assess procedural safety and early outcomes of the Octapro in patients with severe native aortic stenosis (AS) undergoing transcatheter aortic valve implantatio...
A. Ielasi, E. Moscarella, Gregor Verček et al.· International Journal of Car...· 0 citations
TAx-TAVI demonstrated comparable mortality, safety, and hemodynamic outcomes to TF-TAVI, with a significantly lower rate of bleeding complications, and Axillary access represents a safe and effective alternative route in patients unsuitable for transfemoral TAVI.
K. Erdoğan, Emrah Uğuz, M. Erdöl et al.· Diagnostics· 0 citations
Background Mitral regurgitation affects 2% of the population globally, with a widely increasing prevalence. Although mitral regurgitation is most commonly corrected by open surgery, there has been a recent shift toward less invasive transcatheter approaches, including both transcatheter edge‐to‐edge repair (TEER) and t...
Rama Safadi, Alaaeldin Esmail, Lauren E. DeProfio et al.· Cardiovascular Therapeutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.